Vanguard Group Inc. raised its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 4.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,902,246 shares of the biotechnology company's stock after purchasing an additional 221,802 shares during the period. Vanguard Group Inc. owned 5.74% of Anavex Life Sciences worth $42,061,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also modified their holdings of the business. Vermillion Wealth Management Inc. acquired a new stake in shares of Anavex Life Sciences during the fourth quarter worth about $34,000. Tower Research Capital LLC TRC raised its stake in shares of Anavex Life Sciences by 102.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock worth $36,000 after buying an additional 1,708 shares during the period. 180 Wealth Advisors LLC purchased a new stake in shares of Anavex Life Sciences during the first quarter worth approximately $121,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Anavex Life Sciences during the first quarter worth approximately $141,000. Finally, Yukon Wealth Management Inc. purchased a new stake in Anavex Life Sciences in the 1st quarter valued at $147,000. Hedge funds and other institutional investors own 31.55% of the company's stock.
Anavex Life Sciences Stock Up 4.6%
NASDAQ:AVXL traded up $0.42 during mid-day trading on Monday, reaching $9.64. 881,720 shares of the stock were exchanged, compared to its average volume of 883,327. The company has a 50 day simple moving average of $10.54 and a 200-day simple moving average of $9.27. The stock has a market capitalization of $827.98 million, a P/E ratio of -16.91 and a beta of 0.83. Anavex Life Sciences Corp. has a 1 year low of $4.93 and a 1 year high of $14.44.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.03). As a group, research analysts predict that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.
Analyst Ratings Changes
Several equities analysts have recently commented on AVXL shares. D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research note on Wednesday, August 27th. Wall Street Zen lowered Anavex Life Sciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 23rd. Finally, HC Wainwright reiterated a "buy" rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a report on Friday, August 22nd. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $44.00.
Get Our Latest Stock Analysis on Anavex Life Sciences
Anavex Life Sciences Company Profile
(
Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Featured Stories
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
